Bayer elects Werner Wenning as chairman

Monday, September 17, 2012 03:08 PM

Bayer’s  supervisory board has elected Werner Wenning as its chairman, who had already been elected by the Annual Stockholders' Meeting of Bayer in April 27, 2012, to become a member of the supervisory board effective October 1.

Wenning served as chairman of the board of management of Bayer from April 2002 until September 2010. The statutory “cooling-off period,” after which a former member of a company’s board of management may join its supervisory board, ends after two years.

Wenning's career with Bayer spanned nearly 45 years, during which he rose from trainee to CEO. Wenning joined the company in 1966 as a commercial trainee, and subsequently held a number of positions with Bayer in Germany and abroad before being appointed to the board of management as CFO in February 1997. Five years later—in April 2002—he became chairman of the board of management of the pharmaceuticals and chemicals group.

Milestones during Wenning’s tenure as CEO included the strategic realignment of the Bayer Group and the spin-off of the traditional chemicals business under the name Lanxess. The most important and strategically decisive step toward expanding the life science business was the acquisition of Schering, of Berlin, Germany, in 2006.

Share:          
CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs